Completed
OXD01 in Combination With Sublingual Buprenorphine/Naloxone for Treatment of Opioid Use Disorder
NCT04948307
- Conditions
- Chemically-Induced Disorders, Mental Disorders, Narcotic-Related Disorders, +3 more
- Locations
-
- Parkway Medical Center Birmingham, Alabama, United States
- North County Clinical Research Oceanside, California, United States
- Artemis Institute for Clinical Research San Diego, California, United States
- Wetlin Research Associates, Inc San Diego, California, United States